Management and Treatment of Diabetic Macular Edema After Protocol T [SUPPLEMENT]
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Overview
A CME activity jointly provided by Evolve Medical Education LLC, New Retina MD, Retina Today, and Advanced Ocular Care. Supported through an unrestricted educational grant by Regeneron Pharmaceuticals. Learning Objectives
Upon completion of this activity, the participant should be able to: - Assess clinical studies involving new approaches to treat DME, with particular attention to the DRCR.net’s Protocol T
- Differentiate existing DME intravitreal therapy options from recent primary and secondary treatments
- Evaluate treatment options and develop criterion/criteria on when to initiate or alter therapy
- Discuss case scenarios and apply data from recent clinical studies to better manage patients with DME
Accreditation
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, New Retina MD, Retina Today and Advanced Ocular Care. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT Evolve Medical Education LLC (Evolve) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Faculty and Disclosures
DISCLOSURE POLICY
Rishi P. Singh, MD, moderator Cole Eye Institute, Cleveland Clinic Cleveland, Ohio Mandeep Brar, MD Abrazo Medical Group Glendale, Arizona Mark Dunbar, OD Bascom Palmer Eye Institute Miami, Florida John W. Kitchens, MD Retina Associates of Kentucky Lexington, Kentucky DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty members have the following financial relationships with commercial interests: Rishi P. Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Contracted Research: Alcon; Genentech; Regeneron Pharmaceuticals. Mandeep Brar, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Janssen Pharmaceutical; and Regeneron Pharmaceuticals. Mark Dunbar, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Carl Zeiss Meditec; and Regeneron Pharmaceuticals. John W. Kitchens, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Genentech; Synergetics USA; and ThromboGenics NV. Cheryl Cavanaugh, MS, Evolve; Emily Feinman, New Retina MD, Retina Today, Advanced Ocular Care; Michelle Dalton, writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, New Retina MD, Retina Today, Advanced Ocular Care, or Regeneron Pharmaceuticals. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal - CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit












